TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23259262

Group type: EXPERIMENTAL
Intervention: Combined therapy of scalp and body acupuncture by stages (specific acupoints selected based on disease stage).
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined therapy of scalp and body acupuncture by stages.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional acupuncture (no scalp acupuncture, acupoints not selected by disease stage).
Number of subjects: 96
Study: 20855284

Group type: EXPERIMENTAL
Intervention: Bufeishenqingre decoction, administered twice a day for one month.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Theophylline sustained-release capsules, 100 mg administered twice a day for one month.
Number of subjects: 60
Study: 18304674

Group type: EXPERIMENTAL
Intervention: Counseling intervention using continuous glucose monitoring system (CGMS) feedback
Number of subjects: 52

Group type: COMPARATOR
Intervention: Diabetes education (control group)
Number of subjects: 52
Study: 16172456

Group type: EXPERIMENTAL
Intervention: ABI‐007 260 mg/m² intravenously without premedication
Number of subjects: 454

Group type: COMPARATOR
Intervention: Standard paclitaxel 175 mg/m² intravenously with premedication
Number of subjects: 454
Study: 12609940

Group type: EXPERIMENTAL
Intervention: 100 000 IU oral vitamin D3 (cholecalciferol) supplementation every four months
Number of subjects: 2686

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2686
Study: 10591988

Group type: EXPERIMENTAL
Intervention: Sleep phase advance (SPA) - time in bed scheduled from 1700-2400 hrs
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sleep phase delay (SPD) - time in bed from 0200-0700 hrs
Number of subjects: 40
Study: 8946863

Group type: EXPERIMENTAL
Intervention: Adenosquamous cell type
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Adenocarcinoma
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Squamous carcinoma
Number of subjects: 813

Group type: COMPARATOR
Intervention: All cell types
Number of subjects: 813
Study: 1657078

Group type: EXPERIMENTAL
Intervention: CVM (carboplatin 300 mg/m2, vinblastine 6 mg/m2, methotrexate 30 mg/m2, intravenously every 4 weeks)
Number of subjects: 104

Group type: COMPARATOR
Intervention: ACE (doxorubicin 40 mg/m2, cyclophosphamide 600 mg/m2, etoposide 100 mg/m2, intravenously day 1-3, every 3 weeks)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CVM
Number of subjects: 104

Group type: COMPARATOR
Intervention: ACE
Number of subjects: 104
Study: 6816061

Group type: EXPERIMENTAL
Intervention: Food supplementation program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food supplementation program combined with a home education program
Number of subjects: 0
Study: 30729881

Group type: EXPERIMENTAL
Intervention: Problem-solving-based intervention focused on caregiver medication management
Number of subjects: 83

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Problem-solving-based intervention
Number of subjects: 83
Study: 30510434

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 26850307

Group type: EXPERIMENTAL
Intervention: BUD/FM 160/4.5 μg plus as-needed BUD/FM (SMART group, n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: FF/VI 100/25 μg plus as-needed procaterol (FF/VI group, n=15)
Number of subjects: 30
Study: 25140986

Group type: EXPERIMENTAL
Intervention: X3 crosslinked polyethylene (XLPE) liner
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional polyethylene (CPE) liner
Number of subjects: 24
Study: 22429600

Group type: EXPERIMENTAL
Intervention: pedometer-based walking programme plus physical activity consultations
Number of subjects: 79

Group type: COMPARATOR
Intervention: pedometer-based walking programme and minimal advice
Number of subjects: 79
Study: 19842037

Group type: EXPERIMENTAL
Intervention: Couple CARE for Parents (CCP)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Becoming a Parent (BAP)
Number of subjects: 71
Study: 16712981

Group type: EXPERIMENTAL
Intervention: Validation Therapy (VT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sensorial Reminiscence (SR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No Treatment (Control)
Number of subjects: 30
Study: 15844684

Group type: EXPERIMENTAL
Intervention: Screening questionnaire
Number of subjects: 196

Group type: COMPARATOR
Intervention: Screening interview
Number of subjects: 196
Study: 12518931

Group type: EXPERIMENTAL
Intervention: Lisinopril (up to 40 mg/day, with furosemide if needed)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lacidipine (up to 8 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 30
Study: 10520979

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.25 to 4.0 mg in 2 divided doses)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Clonazepam (during tapering)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 438
Study: 7741289

Group type: EXPERIMENTAL
Intervention: Iontophoresis 1.0 mA for 2 h (120 mA.min)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Iontophoresis 2.0 mA for 2 h (240 mA.min)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Passive treatment 0.0 mA for 2 h (0 mA.min)
Number of subjects: 5
Study: 2201625

Group type: EXPERIMENTAL
Intervention: SAFA test
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 6752708

Group type: EXPERIMENTAL
Intervention: J5 antiserum
Number of subjects: 212

Group type: COMPARATOR
Intervention: Preimmune control serum
Number of subjects: 212
Study: 30341695

Group type: EXPERIMENTAL
Intervention: Verum tDCS (2.0 mA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 6
Study: 27666126

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg for 5 days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg plus hydrochlorothiazide 25 mg for 5 days
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg plus torasemide 5 mg for 5 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg for 4 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Torasemide 5 mg for 4 days
Number of subjects: 22
Study: 25710925

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scan
Number of subjects: 473

Group type: COMPARATOR
Intervention: Coronary computed tomographic angiography (CCTA)
Number of subjects: 473
Study: 23589316

Group type: COMPARATOR
Intervention: Conventional chemotherapy (Control group, N=31)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy drugs and intraperitoneal perfusion of verapamil (Combined treatment group, N=41)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (N=31)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combined treatment group (N=41)
Number of subjects: 72
Study: 20620720

Group type: EXPERIMENTAL
Intervention: Benazepril + Amlodipine (B+A)
Number of subjects: 6946

Group type: COMPARATOR
Intervention: Benazepril + Hydrochlorothiazide (B+H)
Number of subjects: 6946

Group type: EXPERIMENTAL
Intervention: Benazepril + Amlodipine (B+A) in very high risk diabetic patients
Number of subjects: 6946

Group type: COMPARATOR
Intervention: Benazepril + Hydrochlorothiazide (B+H) in very high risk diabetic patients
Number of subjects: 6946

Group type: EXPERIMENTAL
Intervention: Benazepril + Amlodipine (B+A) in nondiabetic patients
Number of subjects: 6946

Group type: COMPARATOR
Intervention: Benazepril + Hydrochlorothiazide (B+H) in nondiabetic patients
Number of subjects: 6946
Study: 18391133

Group type: EXPERIMENTAL
Intervention: Combination therapy (COMB)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 439
Study: 16640253

Group type: EXPERIMENTAL
Intervention: Flat-shaded rendering condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiosity rendering condition
Number of subjects: 0
Study: 12781926

Group type: EXPERIMENTAL
Intervention: Individual coaching on communication skills and confidence in health consultations
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control condition (no coaching)
Number of subjects: 384
Study: 10647797

Group type: COMPARATOR
Intervention: Peak CK-MB levels 0-1 times normal
Number of subjects: 8250

Group type: EXPERIMENTAL
Intervention: Peak CK-MB levels 1-2 times normal
Number of subjects: 8250

Group type: EXPERIMENTAL
Intervention: Peak CK-MB levels 3-5 times normal
Number of subjects: 8250

Group type: EXPERIMENTAL
Intervention: Peak CK-MB levels greater than 10 times normal
Number of subjects: 8250
Study: 9233995

Group type: EXPERIMENTAL
Intervention: DCA 2000 system
Number of subjects: 1016
Study: 8245520

Group type: EXPERIMENTAL
Intervention: Group A (1770 pfu/dose)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group B (400‐500 pfu/dose)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group C (80‐160 pfu/dose)
Number of subjects: 90
Study: 3896659

Group type: EXPERIMENTAL
Intervention: Slow-release indomethacin (50 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Naproxen (250 mg)
Number of subjects: 21
Study: 31264055

Group type: EXPERIMENTAL
Intervention: Supervised exercise (n = 36)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Wait-list (WL; n = 18)
Number of subjects: 54
Study: 29023192

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with Methylene Blue dye (0.01%) and laser therapy (660 nm, 30 mW, 8 sec, 6 J/cm2, beam area of 0.04 mm2), three times per week for 10 sessions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group treated with collagenase/chloramphenicol
Number of subjects: 12
Study: 26896305

Group type: EXPERIMENTAL
Intervention: Standard dose of 25‐30 min of aerobic exercise
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Higher dose of 50‐60 min of aerobic exercise
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Combined dose of 50‐60 min of aerobic and resistance exercise
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: High volume program (50‐60 min of aerobic exercise)
Number of subjects: 301
Study: 24886116

Group type: EXPERIMENTAL
Intervention: BAcPAc (behavioural activation combined with physical activity promotion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Behavioural activation alone (treatment as usual)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BAcPAc
Number of subjects: 60

Group type: COMPARATOR
Intervention: Behavioural activation alone
Number of subjects: 60
Study: 23450712

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBTI) delivered in up to eight weekly telephone sessions (CBTI-Phone, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Information pamphlet control (IPC, n = 15)
Number of subjects: 30
Study: 20518172

Group type: EXPERIMENTAL
Intervention: Acupuncture and non-scarring moxibustion (applied on local acupoints of knee, Shenshu (BL 23), and Xuehai (SP 10))
Number of subjects: 62

Group type: COMPARATOR
Intervention: Acupuncture (only)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 62
Study: 18809424

Group type: EXPERIMENTAL
Intervention: Suprathreshold processing of global stimuli for motion and spatial tasks
Number of subjects: 0
Study: 16907968

Group type: EXPERIMENTAL
Intervention: Literacy (measured by the Short‐Test of Functional Health Literacy in Adults)
Number of subjects: 1002
Study: 14509171

Group type: EXPERIMENTAL
Intervention: Endoscopy (Tele‐Otoscope with a 70 degrees viewing angle) used as an intraoperative visualization aid
Number of subjects: 129

Group type: COMPARATOR
Intervention: Micromirrors used for intraoperative diagnostics
Number of subjects: 129
Study: 10641779

Group type: EXPERIMENTAL
Intervention: Intraperitoneal epoetin alfa
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subcutaneous epoetin alfa
Number of subjects: 20
Study: 8648396

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G-CSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSFs (GM-CSF or G-CSF) administered before or during induction therapy and following chemotherapy until neutrophil recovery
Number of subjects: 0
Study: 1794947

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3918430

Group type: EXPERIMENTAL
Intervention: Microbial beta-galactosidases added to 360 ml of cow milk containing 18 g of lactose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intact milk
Number of subjects: 0
Study: 31374252

Group type: EXPERIMENTAL
Intervention: Immediate intervention group (peer-to-peer consultation program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 29757058

Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing THR or TKR
Number of subjects: 587

Group type: COMPARATOR
Intervention: Diabetic patients (well-controlled vs poorly-controlled)
Number of subjects: 587
Study: 29178716

Group type: EXPERIMENTAL
Intervention: Toothpaste containing lysozyme
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 71
Study: 24001105

Group type: EXPERIMENTAL
Intervention: Pumosetrag 0.2 mg
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Pumosetrag 0.5 mg
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Pumosetrag 0.8 mg
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 22752418

Group type: EXPERIMENTAL
Intervention: 1 mg kg(‐1 )day(‐1) ferrous sulfate for 6 months starting at 6 months of age
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no iron supplementation)
Number of subjects: 105
Study: 20863759

Group type: EXPERIMENTAL
Intervention: SLN resection plus ALND (group 1)
Number of subjects: 3989

Group type: COMPARATOR
Intervention: SLN resection alone (group 2)
Number of subjects: 3989
Study: 17913720

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg every 12 h)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Vancomycin (1 g every 12 h)
Number of subjects: 151
Study: 16148176

Group type: EXPERIMENTAL
Intervention: HpSA test (Equipar)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Endoscopy-based tests
Number of subjects: 430
Study: 14607200

Group type: EXPERIMENTAL
Intervention: D-Ribose
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10837450

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 0
Study: 8646953

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1826046

Group type: EXPERIMENTAL
Intervention: Mesoglycan (100 mg/day) for six months
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard anti-platelet treatment for six months
Number of subjects: 145
Study: 6372065

Group type: EXPERIMENTAL
Intervention: Trimipramine (Surmontil), 50 mg at bedtime
Number of subjects: 114

Group type: COMPARATOR
Intervention: Cimetidine (Tagamet), 200 + 200 + 200 + 400 mg/day
Number of subjects: 114
Study: 30205182

Group type: EXPERIMENTAL
Intervention: 1× per week exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3× per week exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study: 28854588

Group type: EXPERIMENTAL
Intervention: D3 SET + Eeva™
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: D5 SET + Eeva™
Number of subjects: 163

Group type: COMPARATOR
Intervention: D5 SET with CM alone
Number of subjects: 163
Study: 25831203

Group type: EXPERIMENTAL
Intervention: Stapler circumcision
Number of subjects: 879

Group type: COMPARATOR
Intervention: Conventional circumcision
Number of subjects: 879
Study: 23210859

Group type: EXPERIMENTAL
Intervention: Solobond M two‐step etch‐and‐rinse adhesive
Number of subjects: 244

Group type: COMPARATOR
Intervention: Futurabond NR one‐step self‐etch adhesive
Number of subjects: 244
Study: 21054750

Group type: EXPERIMENTAL
Intervention: 600 mg ATC
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 800 mg ATC
Number of subjects: 51

Group type: COMPARATOR
Intervention: 150 mg 3TC
Number of subjects: 51
Study: 18506177

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) administered at 2300 hours
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) administered at 1100 hours
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (morning administration)
Number of subjects: 44
Study: 16984725

Group type: EXPERIMENTAL
Intervention: Snacking habit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Habitual negative self‐thinking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task complexity manipulation
Number of subjects: 0
Study: 12853354

Group type: EXPERIMENTAL
Intervention: CPT‐11 125 mg/m(2), FA 20 mg/m(2) followed by 5‐FU 500 mg/m(2) bolus, weekly for 4 weeks (arm A)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: CPT‐11 180 mg/m(2) day 1, FA 200 mg/m(2) over 2 h and 5‐FU 400 mg/m(2) bolus and 5‐FU 600 mg/m(2) 22‐h infusion on days 1 and 2, every 2 weeks (arm B)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: CPT‐11 350 mg/m(2) (days 1 and 43) alternating with FA 20 mg/m(2)/day followed by 5‐FU bolus 425 mg/m(2)/day during 5 days (days 22‐26) (arm C)
Number of subjects: 154
Study: 10778842

Group type: EXPERIMENTAL
Intervention: Complete EMRs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hybrid EMRs
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 16
Study: 8780093

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA) injections
Number of subjects: 66

Group type: COMPARATOR
Intervention: Trihexyphenidyl tablets plus placebo injection
Number of subjects: 66
Study: 1633721

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 1000 mg twice daily
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 500 mg twice daily
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 10 mg/kg twice daily
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 20 mg/kg twice daily
Number of subjects: 305

Group type: COMPARATOR
Intervention: Cefaclor 10 mg/kg 3-times daily
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 500 mg twice daily (elderly subgroup)
Number of subjects: 305
Study: 6360751

Group type: EXPERIMENTAL
Intervention: Indoprofen 400 mg i.v.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pentazocine 30 mg i.v.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31455149

Group type: EXPERIMENTAL
Intervention: Smoking Prevention Education Program (SPEP)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study: 29696654

Group type: EXPERIMENTAL
Intervention: Whey proteins
Number of subjects: 21

Group type: COMPARATOR
Intervention: Casein
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hydrolyzed casein
Number of subjects: 21
Study: 27545050

Group type: EXPERIMENTAL
Intervention: SIS augmentation (Restore Orthobiologic Implant; DePuy, Warsaw, IN, USA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (repair alone)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: SIS augmentation
Number of subjects: 62
Study: 25433525

Group type: EXPERIMENTAL
Intervention: Complex self-management intervention
Number of subjects: 436
Study: 23260038

Group type: EXPERIMENTAL
Intervention: Telephone support provided by a registered nurse
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no telephone support)
Number of subjects: 40
Study: 20838333

Group type: EXPERIMENTAL
Intervention: Automated dispensing system
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control unit (no automated dispensing system)
Number of subjects: 115
Study: 17440529

Group type: EXPERIMENTAL
Intervention: Kale meal (150 g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Kale meal with potassium oxalate drink (150 g kale + 1.26 g OA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Spinach meal (150 g)
Number of subjects: 16
Study: 16913827

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nebivolol
Number of subjects: 70
Study: 12025521

Group type: EXPERIMENTAL
Intervention: Sildenafil (initial dose 50 mg taken 1 h before sexual activity for the first 2 weeks, increased to 100 mg or decreased to 25 mg as needed)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sildenafil and Placebo
Number of subjects: 60
Study: 10396381

Group type: EXPERIMENTAL
Intervention: Tono-Pen at the central cornea
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tono-Pen at the mid-peripheral cornea
Number of subjects: 48

Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mid-peripheral corneal thickness
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Central corneal thickness
Number of subjects: 48
Study: 7486360

Group type: EXPERIMENTAL
Intervention: Prednisone, 20 mg orally every 12 hours for 4 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo, orally every 12 hours for 4 days
Number of subjects: 43
Study: 2151970

Group type: EXPERIMENTAL
Intervention: Laser thermal angioplasty
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard balloon angioplasty
Number of subjects: 25
Study: 7419005

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Number of subjects: 130
Study: 29808473

Group type: EXPERIMENTAL
Intervention: Plasma Volume Expansion (HA-PVX)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sildenafil (HA-SIL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Plasma Volume Expansion with Sildenafil (HA-PVX-SIL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High Altitude (HA)
Number of subjects: 12